标题
Recent advances in breast cancer research impacting clinical diagnostic practice
作者
关键词
-
出版物
JOURNAL OF PATHOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2018-11-14
DOI
10.1002/path.5199
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The immunological consequences of radiation-induced DNA damage
- (2019) Anna C Wilkins et al. JOURNAL OF PATHOLOGY
- Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged
- (2018) Austin D. Williams et al. ANNALS OF SURGICAL ONCOLOGY
- Mechanisms of immune evasion in breast cancer
- (2018) Joshua P. Bates et al. BMC CANCER
- Targeting FGFR pathway in breast cancer
- (2018) J. Perez-Garcia et al. BREAST
- Treatment of advanced HER2-positive breast cancer: 2018 and beyond
- (2018) Noam Pondé et al. CANCER TREATMENT REVIEWS
- Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
- (2018) Sibylle Loibl et al. CLINICAL CANCER RESEARCH
- Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis
- (2018) Matthew N. Mills et al. EUROPEAN JOURNAL OF CANCER
- Heterogeneity of Tumour Infiltrating Lymphocytes (TILs) in Breast Cancer and its prognostic significance
- (2018) Maryam Althobiti et al. HISTOPATHOLOGY
- Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology
- (2018) Amy E McCart Reed et al. JOURNAL OF PATHOLOGY
- Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Angelo Di Leo et al. LANCET ONCOLOGY
- Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast: a comparative study of 9 additional cases
- (2018) Nadjla Alsadoun et al. MODERN PATHOLOGY
- Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
- (2018) Nikolaos Zacharakis et al. NATURE MEDICINE
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- (2018) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of Selective Estrogen Receptor Covalent Antagonists (SERCAs) for the treatment of ERa(WT) and ERa(MUT) breast cancer.
- (2018) Xiaoling Puyang et al. Cancer Discovery
- Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer
- (2018) Ivana Sestak et al. JAMA Oncology
- Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay
- (2018) Michaela Tsai et al. JAMA Oncology
- Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
- (2018) Patrick Danaher et al. Journal for ImmunoTherapy of Cancer
- Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives
- (2018) Enrique Soto-Perez-De-Celis et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer in PALOMA-3
- (2018) Massimo Cristofanilli et al. EUROPEAN JOURNAL OF CANCER
- Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications
- (2018) Amy Ellen McCart Reed et al. JOURNAL OF PATHOLOGY
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB -NFIB fusion gene
- (2017) Jisun Kim et al. JOURNAL OF PATHOLOGY
- Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) José Baselga et al. LANCET ONCOLOGY
- Association analysis identifies 65 new breast cancer risk loci
- (2017) Kyriaki Michailidou et al. NATURE
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
- (2017) Helen Davies et al. NATURE MEDICINE
- Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer
- (2017) Stephen J. Luen et al. PATHOLOGY
- Poly(ADP-ribose) polymerase activity and inhibition in cancer
- (2017) Caleb Dulaney et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
- (2017) François Bertucci et al. Current Oncology Reports
- Prevalence and detection of low-allele-fraction variants in clinical cancer samples
- (2017) Hyun-Tae Shin et al. Nature Communications
- Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer
- (2017) Alberto Peláez-García et al. PLoS One
- Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies
- (2016) Akira I. Hida et al. BREAST CANCER RESEARCH AND TREATMENT
- Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study
- (2016) Sara M. Tolaney et al. BREAST CANCER RESEARCH AND TREATMENT
- Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
- (2016) Shom Goel et al. CANCER CELL
- IDH2Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity
- (2016) Sarah Chiang et al. CANCER RESEARCH
- Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer
- (2016) In Hae Park et al. Clinical Breast Cancer
- A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling
- (2016) H. L. McArthur et al. CLINICAL CANCER RESEARCH
- OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer
- (2016) Robert C Stein et al. HEALTH TECHNOLOGY ASSESSMENT
- Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3
- (2016) Fabrice André et al. JOURNAL OF CLINICAL ONCOLOGY
- PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
- (2016) Charlotte Fribbens et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2016) Lyndsay N. Harris et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic Characterization of Primary Invasive Lobular Breast Cancer
- (2016) Christine Desmedt et al. JOURNAL OF CLINICAL ONCOLOGY
- Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouringTP53somatic mutations
- (2016) Elena Guerini-Rocco et al. JOURNAL OF PATHOLOGY
- Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
- (2016) Richard Buus et al. JNCI-Journal of the National Cancer Institute
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family
- (2016) Felipe C Geyer et al. MODERN PATHOLOGY
- Landscape of somatic mutations in 560 breast cancer whole-genome sequences
- (2016) Serena Nik-Zainal et al. NATURE
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
- (2016) Fatima Cardoso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
- (2016) K. Okkenhaug et al. Cancer Discovery
- ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas
- (2016) Gabrielle Deniziaut et al. Oncotarget
- Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
- (2016) Richard Buus et al. JNCI-Journal of the National Cancer Institute
- Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer
- (2016) Sarat Chandarlapaty et al. JAMA Oncology
- Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
- (2015) Giovanni Ciriello et al. CELL
- Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay
- (2015) A. Prat et al. CLINICAL CANCER RESEARCH
- Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer
- (2015) S. Chia et al. Current Oncology
- Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score
- (2015) Ivana Sestak et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance
- (2015) Jodi M Saunus et al. JOURNAL OF PATHOLOGY
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
- (2015) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
- (2014) S. Loi et al. ANNALS OF ONCOLOGY
- Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
- (2014) H. R. Ali et al. ANNALS OF ONCOLOGY
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Long-term impact of the 70-gene signature on breast cancer outcome
- (2014) C. A. Drukker et al. BREAST CANCER RESEARCH AND TREATMENT
- A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer
- (2014) Komal Jhaveri et al. Clinical Breast Cancer
- The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer
- (2014) Martin Filipits et al. CLINICAL CANCER RESEARCH
- Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Fabrice André et al. LANCET ONCOLOGY
- Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
- (2013) M. Gnant et al. ANNALS OF ONCOLOGY
- Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
- (2013) L Bracci et al. CELL DEATH AND DIFFERENTIATION
- Breast Cancer Index Identifies Early-Stage Estrogen Receptor-Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence
- (2013) Y. Zhang et al. CLINICAL CANCER RESEARCH
- Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
- (2013) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population
- (2013) Dennis C Sgroi et al. LANCET ONCOLOGY
- Mutational landscape and significance across 12 major cancer types
- (2013) Cyriac Kandoth et al. NATURE
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers
- (2013) Steven A Roberts et al. NATURE GENETICS
- Deciphering Signatures of Mutational Processes Operative in Human Cancer
- (2013) Ludmil B. Alexandrov et al. Cell Reports
- Effects of conventional therapeutic interventions on the number and function of regulatory T cells
- (2013) Mario Roselli et al. OncoImmunology
- EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
- (2012) P. Dubsky et al. ANNALS OF ONCOLOGY
- Mutational Processes Molding the Genomes of 21 Breast Cancers
- (2012) Serena Nik-Zainal et al. CELL
- The Life History of 21 Breast Cancers
- (2012) Serena Nik-Zainal et al. CELL
- IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives
- (2012) H. Yang et al. CLINICAL CANCER RESEARCH
- The landscape of cancer genes and mutational processes in breast cancer
- (2012) Philip J. Stephens et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines
- (2011) D. M. Collins et al. ANNALS OF ONCOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
- (2011) S. Modi et al. CLINICAL CANCER RESEARCH
- A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
- (2011) Martin Filipits et al. CLINICAL CANCER RESEARCH
- Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer
- (2011) Jack Cuzick et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin
- (2010) K. Hastak et al. CANCER RESEARCH
- A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer
- (2010) T. O. Nielsen et al. CLINICAL CANCER RESEARCH
- American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
- (2010) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast
- (2010) Felicia Marginean et al. MODERN PATHOLOGY
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group
- (2008) Robert J. Paridaens et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search